Procore signs multi-year strategic collaboration agreement with AWS
Karen DeSalvo, a director at Welltower Inc. (NYSE:WELL), recently sold 4,000 shares of the company’s common stock. The transactions occurred on April 30, 2024, with shares sold at a weighted average price of $151.43, yielding a total of $605,720. Following these sales, DeSalvo holds 11,313.59 shares directly. The sale prices ranged from $151.35 to $151.50 per share.The sale comes as Welltower, a $98.6 billion market cap healthcare REIT, trades near its 52-week high with an impressive 65% return over the past year. InvestingPro analysis indicates the stock is currently overvalued, though it maintains a "GOOD" financial health score and has sustained dividend payments for 50 consecutive years. For deeper insights into Welltower’s valuation and 13 additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Welltower Inc. reported its Q1 2025 earnings, showcasing a net income of $0.40 per diluted share, in line with analyst expectations. The company’s revenue surpassed projections, reaching $2.42 billion compared to the anticipated $2.34 billion, marking a positive surprise for investors. Welltower also revised its full-year 2025 normalized FFO guidance to a midpoint of $4.97 per share, reflecting confidence in continued growth. The company announced significant acquisition activity, including a CAD 4.6 billion deal for Amica Senior Living, adding a high-quality senior housing portfolio to its assets. Additionally, Welltower’s strategic focus on technology and data-driven operations has been recognized with credit rating upgrades from S&P and Moody’s. Analyst firms have noted the company’s strong performance, with some suggesting a positive outlook due to its enhanced competitive positioning. These developments indicate Welltower’s ongoing efforts to strengthen its market presence and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.